Anti-Helicobacter pylori immunoglobulin G (IgG) and IgA antibody responses and the value of clinical presentations in diagnosis of H. pylori infection in patients with precancerous lesions

Shao Li, Ai-Ping Lu, Lian Zhang, Yan-Da Li

Abstract

AIM: To determine the prevalence of Helicobacter pylori (H. pylori) infection, the serum anti-H. pylori immunoglobulin G (IgG) and IgA antibody responses, and the value of clinical presentations in diagnosis of H. pylori infection in patients with gastric atrophy, intestinal metaplasia and dysplasia.

METHODS: H. pylori infection was detected by histology in 209 patients with mild chronic atrophic gastritis (CAG, n=76), severe CAG (n=22), mild intestinal metaplasia (IM, n=22), severe IM (n=58), or dysplasia (DYS, n=31). Serum anti-H. pylori IgG and IgA were double sampled and evaluated by enzyme-linked immunoadsordent assays. 35 clinical presentations were observed and their relationship with H. pylori infection was analyzed by the k-means cluster method.

RESULTS: Both IgG and IgA levels in H. pylori positive patients were significantly higher than those negative for H. pylori (P<0.001-0.01). The prevalence of H. pylori was highest in severe IM (84.5 %), and lowest in mild CAG (51.3 %) (P=0.01). They were similar in severe CAG (68.2 %), mild IM (72.7 %), and DYS (67.7 %). In H. pylori positive patients, the IgG levels in severe CAG were significantly higher than those in mild CAG (P<0.01). In H. pylori negative patients, both IgG and IgA levels increased remarkably in severe IM, compared to those in mild IM (P<0.01-0.05). H. pylori infection exhibited no association with patient’s gender (62.1 % in males; 71.7 % in females) and age (r=0.0814, P=0.241). The diagnostic accuracy based on 35 clinical presentations was 65.7 %. It could be improved by 5.7 % when only the assemblage of digestive symptoms were engaged, or by 8.6 % when the pathogenic factors, general status and grossscopy were combined. The diagnostic accuracy could be decreased when only the general symptoms were engaged, or when the pathogenic factors were accompanied with some common digestive symptoms.

CONCLUSION: H. pylori infection is a major risk factor for the process from atrophy, IM to DYS of gastric mucosa. Serum IgG and IgA are good indicators to evaluate this progress with a certain arrearage. Investigation on the effective assemblages of clinical presentations may provide a better understanding in the pathogenesis, diagnosis and treatment for H. pylori infection.

Li S, Lu AP, Zhang L, Li YD. Anti-Helicobacter pylori immunoglobulin G (IgG) and IgA antibody responses and the value of clinical presentations in diagnosis of H. pylori infection in patients with precancerous lesions. World J Gastroenterol 2003; 9(4): 755-758
http://www.wjgnet.com/1007-9327/9/755.htm

INTRODUCTION

The persistence or repeated infection of pathogenic factors in the stomach may result in the chronic process of gastritis with glandular atrophy (AT), intestinal metaplasia (IM), dysplasia (DYS) and so on at different stages, which indicates diversiform prognosis. The roles of immune reactions in Helicobacter pylori (H. pylori) pathogenesis and chronic gastritis (CG) are research areas of rapid progress[1-4]. It is now recognized that the clinical detection of serum antibody is effective in monitoring the H. pylori infection[5,6]. However, H. pylori infection and the levels of serum anti-H. pylori immunoglobulin antibodies at different stages of CG are not fully investigated. Moreover, the complex clinical manifestations of H. pylori infection and associated CG leads to a diagnostic and therapeutic dilemma for CG[7].

To determine the prevalence of H. pylori infection, the serum anti-H. pylori immunoglobulin G (IgG) and IgA antibody responses, and the value of clinical presentations in diagnosis of H. pylori infection in patients with gastric atrophy, intestinal metaplasia and dysplasia a population-based investigation was designed and a novel analytic method was proposed in this work. The study also took a different perspective in assessing the association between H. pylori infection and clinical presentations.

MATERIALS AND METHODS

Patients

A total of two hundred and nine patients with chronic gastritis, who were diagnosed through gastroscopy and mucosal biopsy, were included in the present study. All patients, who resided in Shandong province, were investigated by the Institute of Basic Theory, Chinese Academy of Traditional Chinese Medicine from 1999 to 2001. Among them 103 were males and 106 were females, aged from 45 to 72 with a mean age of 55 years old. Gastric biopsies were histologically evaluated for activity and chronicity of gastritis, and the presence of AT and/or IM according to the criterion of the visual analogue scale in Sydney classification and grading of gastritis[8]. The patients consisted of 76 with mild chronic atrophic gastritis (CAG), 22 with severe (CAG), 22 with mild IM, 58 with severe IM and 31 with DYS accompanied with mild IM. All patients had not received any anti- H. pylori treatment.
Diagnosis of H. pylori infection

Two hundred and nine specimens of gastric mucosa were obtained from each patient via endoscopy. Gastric mucosa was sampled from the area of greater curvature at gastric antrum, and H. pylori was determined by pathological staining with hematoxylin and eosin (HE) followed by Giemsa staining. Under microscope, Helicobacter-like organisms can be identified as a typical curve like S or C. They look like a short bacilli or globular body with a slight curve.

Detection of anti-H. pylori IgG and IgA antibodies

Blood was sampled twice from patients. Enzyme-linked immunosorbent assays (ELISA) were used to detect the levels of serum anti-H. pylori IgG and IgA antibodies. The test kits for the detection of anti-H. pylori IgG and anti-H. pylori-IgA were purchased from Biosense Co., USA. The value of the optical density (OD) was read by a microtiter plate reader at 450 nm.

Clinical presentations observation

35 clinical presentations were observed as follows: (1) Symptoms of the digestive system including appetite, distending fullness in the stomach, stomachache, distending fullness in the abdomen, pain in the hypochondrium, pain in the abdomen, singultus, nausea, vomit, acid regurgitation and epigastric upset, and heartburn; (2) General status including ear, eye, physique, complexion, stool, urine, oropharynx, taste, swollen, head, limbs, chest, hand and foot; (3) Spirit and psychological status including spirit, sleep, and emotion; (4) Glossoscopy including quality of tongue, body of tongue, and fur of tongue and (5) Pathogenic factors including smoking, alcohol, dietary bias, and dietary regularity. Each investigated symptom consisted of two to four subordinate items.

Statistical analysis

A SPSS 10.0 statistical package program was used for data analysis. The variables were processed by chi-square test, student’s t test, ANVOA analysis, and bivariate correlate analysis, where appropriate.

Table 1

| H. pylori | Mild CAG | Severe CAG | Mild IM | Severe IM | DYS | Total |
|----------|----------|------------|--------|----------|-----|-------|
| Number | 76       | 22         | 16     | 47       | 66  | 80    |
| Positive % | 39 (51.3%) | 15 (68.2%) * | 16 (72.7%) | 49 (84.5%) | 6 (15.5%) | 9 (15.5%) |
| Negative % | 37 (48.7%) | 7 (31.8%) | 6 (27.3%) | 9 (15.5%) | 57 (84.5%) | 69    |

CAG, chronic atrophic gastritis; IM, intestinal metaplasia; DYS, dysplasia. P <0.05, *P <0.01, mild IM vs severe IM; mild CAG vs. severe CAG.

Table 2

| H. pylori | Males | Females | 70-77 years old | 60-69 years old | 50-59 years old | 42-49 years old |
|----------|-------|---------|----------------|----------------|----------------|----------------|
| Number | 103   | 106     | 16             | 47             | 66             | 80             |
| Positive % | 64 (62.1%) | 76 (71.7%) | 10 (62.5%) | 32 (68.1%) | 39 (59.1%) | 59 (73.8%) |
| Negative % | 39 (37.9%) | 30 (28.3%) | 6 (37.5%) | 15 (31.9%) | 27 (40.9%) | 21 (26.2%) |

Table 3

| H. pylori | Mild CAG | Severe CAG | Mild IM | Severe IM | DYS |
|----------|----------|------------|--------|----------|-----|
| IgG(1) | 2.86±1.8 * | 0.38±0.27 | 4.48±2.14 * | 0.53±0.27 | 3.86±1.8 * | 0.14±0.07 | 3.12±3.4 * | 0.55±0.29 * | 2.74±1.6 * | 0.23±0.17 |
| IgG(2) | 3.26±2.16 * | 0.46±0.24 | 4.52±2.7 * | 0.54±0.29 | 4.44±2.56 * | 0.3±0.18 | 3.51±1.98 * | 0.54±0.29 | 3.3±1.87 * | 0.72±0.97 |
| IgA(1) | 0.85±0.7 * | 0.24±0.22 | 0.99±0.49 | 0.21±0.16 | 0.83±0.39 | 0.1±0.06 | 0.93±0.79 | 0.33±0.16 | 0.94±0.89 | 0.13±0.13 |
| IgA(2) | 0.96±0.83 * | 0.25±0.21 | 1.08±0.59 | 0.27±0.16 | 0.99±0.72 | 0.12±0.07 | 0.89±0.63 | 0.32±0.19 | 0.78±0.6 | 0.15±0.13 |

CAG, chronic atrophic gastritis; IM, intestinal metaplasia; DYS, dysplasia. (1) The first detection. (2) The second detection. P <0.01, *P <0.001, H. pylori (+) vs. H. pylori (-). P <0.05, H. pylori (+) mild CAG vs. H. pylori (+) severe CAG; *P <0.05, H. pylori (-) mild IM vs. H. pylori (-) severe IM.
Table 4 Diagnostic accuracy of H. pylori infection determined by different assemblages of symptoms

| Attributes                        | Assemblages of symptoms                                              | H. pylori (+) | H. pylori (-) |
|----------------------------------|-----------------------------------------------------------------------|---------------|---------------|
| **Pathogenic factors and general status** | Smoking, alcohol, limbs, hand and foot (all*)                                 | 70.7%         | 42.3%         |
| **Pathogenic factors, general status and tongue** | Smoking, alcohol, dietary regularity, limbs, and tongue quality (all*)                              | 74.3%         | 39.1%         |
| **Pathogenic factors and digestive symptoms** | Smoking, alcohol, limbs, hand and foot, distending fullness in the stomach, stomachache, distending fullness in the abdomen, and nausea (all*) | 51.4%         | 52.2%         |
| **Digestive symptoms**            | Appetite, distending fullness in the stomach, stomachache, distending fullness in the abdomen, pain in the hypochondrium, pain in the abdomen, singultus, nausea, vomit, acid regurgitation and epigastric upset, heartburn, and stool (all*) | 71.4%         | 26.1%         |
| **Digestive symptoms and tongue**  | Distending fullness in the stomach, stomachache, pain in the abdomen, nausea, and fur of tongue (all*) | 72.1%         | 26.3%         |
| **General status**                | Taste, swollen, head, limbs, chest, hand and foot, spirit and sleep, emotion, complexion (all*)     | 50.7%         | 40.6%         |
| **Total symptoms**                | 35 items                                                               | 65.7%         | 40.6%         |

*P < 0.05-0.001, the difference between two classes tested by the ANOVA analysis. **P <0.05-0.001, except dietary bias, dietary regularity, urine, oropharynx, eye, ear, physique, tongue quality, and tongue body.

Table 4 shows the diagnostic accuracy of H. pylori infection determined by different assemblages of clinical presentations. The overall diagnostic accuracy based on 35 presentations was 65.7%. It could be improved by 5.7% when the only digestive symptoms were engaged, or by 8.6% when further information were referred such as the assemblage of pathogenic factors (smoking, alcohol), general status (tired limbs), and tongue observation according to the traditional Chinese medicine (TCM) method. However, the diagnostic accuracy could be decreased by the improper assemblages such as the general symptoms only, the pathogenic factors accompanied with some common digestive symptoms (distending fullness in the stomach, stomachache, distending fullness in the abdomen, and nausea) which had no special significance for the positive or negative H. pylori.

**DISCUSSION**

An increasing number of studies support a close relationship between H. pylori infection and CG, as previously described. However, the correlation between H. pylori infection, serum antibody and clinical symptoms at different stages of CG has not been well investigated so far. The chi-square test results in Table 1 show that the detected positive rates of H. pylori increase significantly in patients with mild CAG (51.3%, 39/76), Dys and mild IM (67.7%, 21/31), severe CAG (68.2%, 15/22), and mild IM (72.7%, 16/22). They reach the highest value in patients with severe IM (84.5%, 49/58) (P < 0.01). However, H. pylori infection exhibited no remarkable association with patient’s gender (62.1% in males; 71.7% in females) and age (r = 0.08, P = 0.241).

It has been reported that the adherence of H. pylori may play an important role in the pathogenesis of severe histological changes in CAG[10], IM[11] and Dys[12]. Our investigation further explored the statistic probability of H. pylori infection at different stages of CG. Based on these, we suggest that H. pylori infection may be the key factor in accelerating the occurrence and development of CG, since H. pylori is a pathogenic bacterium that can adhere to gastric mucosa until the atrophy and intestinal metaplasia occurring in the course of CG.

A mostly pathological mechanism of H. pylori infection is the immunopathological response of host. When CG occurs, a detectable specific humoral immunological response will be established. The appearance of serum antibodies such as IgG and IgA may indicate an extensive immunoreaction causing by H. pylori infection. The serum anti-H. pylori-IgG antibody, therefore, acts as a highly accurate, simple and noninvasive method in monitoring the status of H. pylori infection[13, 14]. In our study, both serum anti-H. pylori IgG and IgA are remarkably higher in H. pylori positive patients than those negative for H. pylori (P < 0.001-0.01). On the one hand, in the presence of H. pylori infection the IgG level in severe CAG increased significantly, compared to those in mild CAG (P < 0.01). These imply that the serum anti-H. pylori IgG and IgA are appropriate indicators to evaluate the status of H. pylori infection in the process of CG. On the other hand, in absence of H. pylori infection both serum IgG and IgA are significantly greater in severe IM than those in mild IM (P < 0.01-0.05), whereas no significant difference (P > 0.05) was observed between mild and severe IM in the presence of H. pylori infection. The increase of antibody may be due to the reminiscence of H. pylori infection, resulting in a certain arrearage between serum antibody and H. pylori. It is reported that the IgA response of gastric mucoa in CG patients can be detected even in the quiescent period of negative H. pylori infection due to the recent exposure to the bacterial antigens[15].

The clinical situations of CG patients are intricate. They are divergent by the pathological changes of gastric mucosa, and are affected by environmental factors[16, 17]. By means of the cluster analysis method, we found that the proper assemblages such as digestive symptoms, pathogenic factors (smoking, alcohol), general status (tired limbs), and the tongue could improve the diagnostic accuracy of H. pylori infection. However, the improper assemblages, such as the general symptoms only, or the pathogenic factors accompanied with some common digestive symptoms decreased the diagnostic accuracy. A preferable symptomatic assemblage has been proposed in the present study. Based on this, the diagnostic accuracies of up to 74.3% and 40.5%, respectively, for positivity and negativity of H. pylori infection have been obtained. It has been demonstrated clinically that smoking, alcohol[16] and the tongue change[17] are pathogenic factors for the H. pylori infection. Our study indicates that the symptomatic assemblages rather than an individual factor are closely related to the clinic significance of H. pylori infection. Furthermore, it has been known that the validity of CG treatment in traditional Chinese medicine (TCM) is based on the differentiation of symptom-complexes[18, 19]. Our investigation suggests that H. pylori-related symptomatic assemblages can be taken into consideration in practicality and methodology during the diagnoses and treatment of CG. More effective symptomatic assemblages and their effects...
on *H. pylori* infection are still required.

In conclusion, the early genesis and further progression of CG are associated with *H. pylori* infection, which can be characterized by the increase of serum anti-*H. pylori* IgG and IgA with a certain arrearage. Due to the intricate clinical situation of CG, effective symptomatic assemblages are required in diagnosing *H. pylori* infection.

**REFERENCES**

1. **Aguilar GR**, Ayala G, Fierros-Zarate G. *Helicobacter pylori*: Recent advances in the study of its pathogenicity and prevention. *Salud Publica Mex*. 2001; **43**: 237-247

2. **Gao HJ**, Yu LZ, Bai JP, Peng YS, Sun G, Zhao HL, Miu K, Lu XZ, Zheng SY, Zhao ZQ. Multiple genetic alterations and behavior of cellular biology in gastric cancer and other mucosal lesions: *H. pylori* infection, histological types and staging. *World J Gastroenterol*. 2000; **6**: 848-854

3. **Zhuang XQ**, Lin SR. Research of *Helicobacter pylori* infection in precancerous gastric lesions. *World J Gastroenterol*. 2000; **6**: 428-429

4. **Prinz C**, Schoniger M, Rad R, Becker I, Keiditsch E, Wagenpfeil S, Classen M, Rosch T, Scheppe G, Gerhard M. Key importance of the *Helicobacter pylori* adherence factor blood group antigen binding adhesin during chronic gastric inflammation. *Cancer Res*. 2001; **61**: 1903-1909

5. **Zhu Y**, Lin J, Li D, Du Q, Qian K, Wu Q, Zheng S. *Helicobacter pylori* antigen and its IgG, IgA-type specific immunocomplexes in sera from patients with *Helicobacter pylori* infection. *Chin Med J (Engl)*. 2002; **115**: 381-383

6. **Futagami S**, Takahashi H, Norose Y, Kobayashi M. Systemic and local immune responses against *Helicobacter pylori* urease in patients with chronic gastritis: distinct IgA and IgG productive sites. *Gut*. 1998; **43**: 168-175

7. **Stankiewicz JA**, Chow JM. A diagnostic dilemma for chronic rhinosinusitis: definition accuracy and validity. *Am J Rhinol*. 2002; **16**: 199-202

8. **Dixon MF**, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis: the updated Sydney system. *International workshop on the histopathology of gastritis* 1994. *Am J Surg Pathol*. 1996; **20**: 1161-1181

9. **Han JW**, Kamber M. Data mining: concepts and techniques. Morgan Kaufmann Publishers, USA 2001: 16

10. **Domellof L*. Reversal of gastric atrophy after *Helicobacter pylori* eradication: is it possible or not? *Am J Gastroenterol*. 1998; **93**: 1407-1408

11. **Meining A**, Stolte M. Close correlation of intestinal metaplasia and corpus gastritis in patients infected with *Helicobacter pylori*. *Z Gastroenterol*. 2002; **40**: 557-560

12. **Gao H**, Wang JY, Shen XZ, Liu JJ. Effect of *Helicobacter pylori* infection on gastric epithelial cell proliferation. *World J Gastroenterol*. 2000; **6**: 442-444

13. **Figueroa G**, Faundez G, Troncoso M, Navaire P, Toledo MS. Immunoglobulin G antibody response to infection with coc-coid forms of *Helicobacter pylori*. *Clin Diagn Lab Immunol*. 2002; **9**: 1067-1071

14. **Kipen HM**, Fiedler N. The role of environmental factors in medically unexplained symptoms and related syndromes: conference summary and recommendations. *Environ Health Perspect*. 2002; **110**(Suppl 4): 591-595

15. **Brown LM**, Thomas TL, Ma JL, Chang YS, You WC, Liu WD, Zhang L, Pee D, Gail MH. *Helicobacter pylori* infection in rural China: demographic, lifestyle and environmental factors. *Int J Epidemiol*. 2002; **31**: 628-645

16. **Kamada T**, Haruma K, Komoto K, Mihara M, Chen X, Yoshihara M, Sumii K, Kajiyama G, Tahara K, Kawamura Y. Effect of smoking and histological gastritis severity on the rate of *H. pylori* eradication with omeprazole, amoxicillin, and clarithromycin. *Helicobacter*. 1999; **4**: 204-210

17. **Ozdemir A**, Mas MR, Sahin S, Saglamkaya U, Ateskan U. Detection of *Helicobacter pylori* colonization in dental plaques and tongue scrapings of patients with chronic gastritis. *Quintessence Int*. 2001; **32**: 131-134

18. **Chen ZQ**, Chen GL, Li XY, Zhao YQ, Shi LJ. Plasma L-ENK, AVP, ANP and serum gastrin in patients with syndrome of Liver Qi-stagnation. *World J Gastroenterol*. 1999; **5**: 61-63

19. **Zhang XC**, Gao RF, Li BQ, Ma LS, Ma LX, Wu YZ, Liu FQ, Liao ZL. Clinical and experimental study of therapeutic effect of Weixibaonizhuans pills on gastric precancerous lesions. *World J Gastroenterol*. 1998; **4**: 24-27

Edited by Xia HHX